Hereditary B
deficiency I
of I
the I
fifth I
component I
of I
complement I
in O
man O
. O

The O
first O
recognized O
human O
kindred O
with O
hereditary B
deficiency I
of I
the I
fifth I
component I
of I
complement I
( O
C5 O
) O
is O
described O
. O

The O
inactivation O
of O
the O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
tumor I
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
VHL B
cancer I
syndrome I
and O
is O
associated O
with O
sporadic B
renal I
cell I
carcinomas I
( O
RCC B
) O
and O
brain B
hemangioblastomas I
. O

Somatic O
PTEN O
deletions O
and O
mutations O
were O
observed O
in O
sporadic B
breast I
, I
brain I
, I
prostate I
and I
kidney I
cancer I
cell O
lines O
and O
in O
several O
primary O
tumours B
such O
as O
endometrial B
carcinomas I
, O
malignant B
melanoma I
and O
thyroid B
tumours I
. O

In O
addition O
, O
PTEN O
was O
identified O
as O
the O
susceptibility O
gene O
for O
two O
hamartoma B
syndromes I
Cowden B
disease I
( O
CD B
; O
MIM O
158350 O
) O
and O
Bannayan B
- I
Zonana I
( I
BZS I
) I
or I
Ruvalcaba I
- I
Riley I
- I
Smith I
syndrome I
( O
MIM O
153480 O
) O
. O

The O
overlap O
in O
clinical O
features O
and O
the O
presence O
, O
in O
the O
same O
genes O
, O
of O
mutations O
for O
more O
than O
one O
craniosynostotic B
condition I
- O
such O
as O
Saethre B
- I
Chotzen I
, I
Crouzon I
, I
and I
Pfeiffer I
syndromes I
- O
support O
the O
hypothesis O
that O
TWIST O
and O
FGFRs O
are O
components O
of O
the O
same O
molecular O
pathway O
involved O
in O
the O
modulation O
of O
craniofacial O
and O
limb O
development O
in O
humans O
. O
. O

Mutations O
in O
the O
HEXA O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
A O
( O
Hex O
A O
) O
, O
that O
abolish O
Hex O
A O
enzyme O
activity O
cause O
Tay B
- I
Sachs I
disease I
( O
TSD B
) O
, O
the O
fatal O
infantile B
form I
of I
G I
( I
M2 I
) I
gangliosidosis I
, I
Type I
1 I
. O

Maternal B
uniparental I
disomy I
( I
UPD I
) I
for I
chromosome I
15 I
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

Deficiency B
of I
the I
ninth I
component I
of I
human I
complement I
( O
C9 O
) O
is O
the O
most O
common O
complement B
deficiency I
in O
Japan O
but O
is O
rare O
in O
other O
countries O
. O

Reversal O
of O
severe O
hypertrophic B
cardiomyopathy I
and O
excellent O
neuropsychologic O
outcome O
in O
very B
- I
long I
- I
chain I
acyl I
- I
coenzyme I
A I
dehydrogenase I
deficiency I
. O

Very B
- I
long I
- I
chain I
acyl I
- I
coenzyme I
A I
dehydrogenase I
( I
VLCAD I
) I
deficiency I
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
morbidity O
and O
mortality O
. O

Our O
data O
suggest O
that O
the O
C O
to O
A O
mutation O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
of O
the O
CYP27 O
gene O
not O
only O
causes O
the O
deficiency B
in I
the I
sterol I
27 I
- I
hydroxylase I
activity I
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
mRNA O
splicing O
of O
the O
gene O
. O

This O
study O
reports O
on O
six O
cases O
of O
deficiency B
in I
the I
human I
complement I
regulatory I
protein I
Factor I
H I
( O
FH O
) O
in O
the O
context O
of O
an O
acute B
renal I
disease I
. O

Deficiency B
of I
the I
sixth I
component I
of I
human I
complement I
( O
C6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
Cape O
, O
South O
Africa O
. O

